Sanofi’s big pivot: they’re scrapping amlitelimab, their once-promising eczema drug, after trials showed it didn’t outperform existing treatments — a major reversal just months after hype, following a leadership overhaul and a $1.1B acquisition. While it’s dead for atopic dermatitis, the drug’s still in play for celiac disease, with results due late 2026 — and Sanofi’s 2026 financial outlook remains intact.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
